Do not initiate in rapidly or acutely deteriorating COPD or asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist ...
The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler ... Breo Ellipta and Anoro Ellipta. Trelegy is also indicated to reduce exacerbations of COPD in patients ...
GlaxoSmithKline has filed its new COPD triple therapy with ... could help erase the slow start of Breo and Anoro[/caption] Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium ...
GlobalData on MSN19d
Are dry powder inhalers the key to sustainable respiratory care?Companies like AstraZeneca and GSK, which have high-revenue-generating inhalers for asthma and chronic obstructive pulmonary ...
Researchers are looking at ways to boost the performance and lower the environmental impact of millions of inhalers used for treating asthma and COPD. Working with drug manufacturer Kindeva, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback